Biden’s Cancer Initiative May Intensify Industry, Government Collaboration
Executive Summary
Drug companies and NIH embrace Vice President’s call for moonshot to cure cancer; Amgen and Celgene join separate coalition to test 60 molecules in combination Phase II studies.
You may also be interested in...
Clinical Trial Challenges: FDA Wants More Prospective Studies, Validated Biomarkers
NIH Director Collins and FDA Commissioner Califf discuss difficulties with ‘big science,’ ‘small crappy trials,’ and ‘data landlords.’
Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.
Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.